Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is an open label, dose escalation study to determine the safety and tolerability and
maximum tolerated dose of pazopanib combined with weekly paclitaxel and carboplatin in
patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
GlaxoSmithKline National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey